News & Events
Guangzhou, July 14, 2026 — Guangzhou Lupeng Pharmaceutical Co., Ltd. has reached another important R&D milestone: the first patient has been successfully enrolled in the Phase Ib/II clinical study (CTR20261866, study ID LP-10822) evaluating rocbrutinib in combination with lacutoclax for the treatment of B-cell malignancies.
LP-10822 study is a national multicenter, open-label, single-arm clinical study in China, consisting of two phases: a Phase Ib dose-escalation stage and a Phase II efficacy exploration stage. Phase Ib is designed to evaluate the safety, tolerability, dose-limiting toxicities and pharmacokinetic profile of the combination therapy in patients with mature B-cell malignancies. The study results from Phase Ib will determine the maximum tolerated dose and establish the recommended dose for Phase II. Phase II will further assess the safety, pharmacokinetics and clinical efficacy of the combination regimen.
The study is led by Professor Qiu Lugui from Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences (IHCAMS) in collaboration with multiple clinical research centers nationwide.
Both investigational drugs are novel anti-tumor agents independently innovated by Lupeng Pharmaceutical. Rocbrutinib is the world's first fourth-generation BTK inhibitor with a dual covalent and non-covalent mechanism and has been granted accelerated approval in China. Lacutoclax（LP-108）, as a novel oral, potent and highly selective BCL-2 inhibitor, has demonstrated outstanding clinical efficacy and an excellent safety profile as monotherapy in relapsed/refractory B-cell malignancies. Clinical data presented at major international hematology congresses such as EHA and ASH have earned wide recognition in the field.
Dr. Shen Yue, Senior Vice President of Guangzhou Lupeng Pharmaceutical stated that rocbrutinib and lacutoclax offer complementary advantages and a potent combination, with the potential to establish a novel and highly effective therapeutic regimen. The company is fully committed to advancing this study and looks forward to achieving positive results soon, thereby providing patients with B-cell malignancies with better and more diverse treatment options, contributing to the improvement of diagnosis and treatment standards for hematological malignancies.
Forward-Looking Statements：This press release contains forward-looking statements, including those regarding clinical development timelines, regulatory progress, and the potential therapeutic benefits of rocbrutinib and lacutoclax. These statements are subject to risks and uncertainties that could cause actual results to differ materially.